00:55:19 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-20 Kvartalsrapport 2024-Q3
2024-08-28 Kvartalsrapport 2024-Q2
2024-06-07 Ordinarie utdelning LIPI 0.00 SEK
2024-06-05 Årsstämma 2024
2024-05-22 Kvartalsrapport 2024-Q1
2024-02-28 Bokslutskommuniké 2023
2023-11-22 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-06-09 Ordinarie utdelning LIPI 0.00 SEK
2023-06-08 Årsstämma 2023
2023-05-11 Kvartalsrapport 2023-Q1
2023-02-22 Bokslutskommuniké 2022
2023-01-17 Extra Bolagsstämma 2022
2022-11-23 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-06-03 Ordinarie utdelning LIPI 0.00 SEK
2022-06-02 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-06-09 Ordinarie utdelning LIPI 0.00 SEK
2021-06-08 Årsstämma 2021
2021-06-08 Extra Bolagsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-23 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-08-11 Extra Bolagsstämma 2020
2020-06-12 Ordinarie utdelning LIPI 0.00 SEK
2020-06-11 Årsstämma 2020
2020-05-19 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019
2019-11-21 Kvartalsrapport 2019-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Lipidor är verksamt inom läkemedelsbranschen. Bolaget arbetar med forskning och utveckling inom preklinisk samt klinisk fas. Störst affärsverksamhet återfinns inom utveckling av läkemedel som vidare används för behandling av diverse hudsjukdomar. Exempel på sjukdomar som behandlas inkluderar exempelvis psoriasis, olika hudinfektioner samt atopisk dermatit. Huvudkontoret ligger i Solna.
2022-03-25 11:30:00
STOCKHOLM, Sweden, 25 March 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) is announcing that the company has strengthened its operational team with the recruitment of Marianne Avila to the position of Supply Chain & Operations Manager.

At Lipidor, Marianne Avila will strengthen the operational team and contribute to development, primarily in purchasing and logistics, which are vital functions as the company approaches commercialization. Lipidor already has a commercial agreement in place, and work is underway for additional commercial contracts, for the company's drug candidates for the treatment of psoriasis.

Marianne Avila took up the newly created position during the month of March, and reports to the Chief Development Officer, Anders Hagman. Her background and experience include areas such as purchasing, logistics, sales and regulatory issues in the pharmaceutical industry, including at FrostPharma AB, Air Liquide Gas AB, AstraZeneca and from Stockholm Regional Council, where she worked in procurement of pharmaceuticals. Marianne holds a master's degree in molecular biology from Purdue University in the United States.

"It is gratifying to welcome Marianne Avila to Lipidor. Recruitment to the new position of Supply Chain & Operations Manager is a natural step in strengthening our operational team, ahead of the company's continued development. Lipidor is now entering a new phase and we are preparing for a commercialization of our psoriasis candidates,” says Ola Holmlund, CEO of Lipidor.

Publication

The information was provided for publication by Lipidor’s CEO on 25th March 2022 at 11.30am (CET).